Subtyping strokes using blood-based biomarkers: A proteomics approach

 $\ddot{\mathbf{S}}$ Shubham Misra-2, Praveen Singh-, Shantanu Sengupta-, Manoj Kushwaha-, Zuhaibur
Rahman³, Divya Bhalla³, Pumanshi Talwar¹, Manabesh Nath¹, Rahul Chakraborty³,
Pradeep Kumar¹. Amit Kumar^{1,4}. Praveen Aggarwal⁵. Rahman°, Divya Bhalla°, Pumanshi Talwar°, Mahabesh Nath°, Rahul Chakraborty°,
Pradeep Kumar¹, Amit Kumar^{1,4}, Praveen Aggarwal⁵, Achal K Srivastava¹, Awadh K
Pandit¹ Dheerai Mohania⁶ Kameshwar Prasad^{1,7} Deepti Pandit¹, Dheeraj Mohania⁶, Kameshwar Prasad^{1,7}, Deepti Vibha^{1*}

 4 Department of Neurology, All India Institute of Medical Sciences, New Delhi, India $\frac{1}{2}$

²Department of Neurology, Yale University School of Medicine, New Haven, CT
³CSIR-Institute of Genomics and Integrative Biology, New Delhi, India

-Department of Neurology, rale University School of Medicine, New Haven, CT
³CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
⁴Department of Laboratory Medicine. Raiendra Institute of Medical Scienc

°CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
⁴Department of Laboratory Medicine, Rajendra Institute of Medica
India Department of Laboratory Medicine, Rajendra Institute of Medical Sciences, Ranchi,
India
⁵Department of Emergency Medicine. All India Institute of Medical Sciences. New Delhi.

⁵Depa
India 5Department of Emergency Medicine, All India Institute of Medical Sciences, New Delhi,
India
⁶Dr. R.P. Centre. All India Institute of Medical Sciences. New Delhi. India

⁶Dr. R
⁷Depa

 7 Department of Neurology, Rajendra Institute of Medical Sciences, Ranchi, India pepartment of Neurology, Rajendra Institute of Medical Sciences, Ranchi, India
Corresponding author details:

\overline{a} Corresponding author details:

$\begin{array}{c} \n\cdot \\
\cdot\n\end{array}$ Dr. Deepti Vibha

Professor
Room No.: 707, 7th Floor

Department of Neurology \mathcal{D} - \mathcal{D} and \mathcal{D} and \mathcal{D} and \mathcal{D}

Neurosciences Centre
All India Institute of Medical Sciences

Ansari Nagar, New Delhi-110029, India
PH: +91-11-26594485

بر
191-11-26594485
Email ID: deeptivibha@gmail.com PH: +91-11-11-1
Email ID: <u>deeptivibha@</u>

Total Word Count: 3996 $\ddot{}$

Total number of tables: 4

Total number of figures: 3
|
| Total number of figures: 3

Abstract
Background and Objectives: Rapid diagnosis of stroke and its subtypes is critical in early stages. We aimed to discover and validate blood-based protein biomarkers to differentiate ischemic stroke (IS) from intracerebral hemorrhage (ICH) within 24 hours
using high-throughput proteomics. $\lim_{\delta \to 0} \frac{d}{dt}$ is the intracered intracered the more intracered to the more extension of δ .

Methods: We collected serum samples within 24 hours from acute stroke (IS & ICH) and mimics patients. In the discovery phase, SWATH-MS proteomics identified differentially expressed proteins (fold change: 1.5, p<0.05, and confirmed/tentative
selection using Boruta random forest) between IS and ICH which were validated using differentially expressed to the selection using Boruta random forest) between IS and ICH which were validated using
Multiple Reaction Monitoring (MRM) proteomics in the validation phase. Proteinselection discriber of the Validation phase. Protein-
Multiple Reaction Monitoring (MRM) proteomics in the validation phase. Protein-
Interactions and pathway analysis were conducted using STRING version 11 and Cytoscape 3.9.0. Cut-off points were determined using Youden Index. Prediction protein interactions and pathway analysis were conducted using volden Index. Prediction
and Cytoscape 3.9.0. Cut-off points were determined using Youden Index. Prediction
models were developed using backward stepwise multi models were developed using backward stepwise multivariable logistic regression analysis. Hanley-McNeil test, Integrated discrimination improvement index, and likelihood ratio test determined the improved discrimination ability of biomarkers
added to clinical models. likelihood ratio test determined the improved discrimination ability of biomarkers
added to clinical models.

Results: Discovery phase included 20 IS and 20 ICH while validation phase included 150 IS, 150 ICH, and 6 stroke mimics. We quantified 365 proteins in the discovery phase. Between IS and ICH, we identified 20 differentially expressed proteins. In the validation phase, combined prediction model including three biomarkers: GFAP (OR 0.04; 95%CI 0.02-0.11), MMP9 (OR 0.09; 95%CI 0.03-0.28), APO-C1 (OR 5.76; 95%CI 2.66-12.47) and clinical variables independently differentiated IS from ICH (accuracy: 2.66-12.47) and clinical variables independently differentiated IS from ICH (accuracy:

92%, sensitivity: 96%, specificity: 69%). Addition of biomarkers to clinical variables
improved the discrimination capacity by 26% (p<0.001). Subgroup analysis within 6 hours identified that GFAP and MMP9 differentiated IS from ICH with a sensitivity>
90%. 90% .

Conclusions: Our study identified that GFAP, MMP, and APO-C1 biomarkers Conclusions: Our study identified that GFAP, MMP, and APO-C1 biomarkers
independently differentiated IS from ICH within 24 hours and significantly improved
the discrimination ability to predict IS. Temporal profiling of th independently differentiated IS from ICH within 24 hours and significantly improved
the discrimination ability to predict IS. Temporal profiling of these biomarkers in the
acute phase of stroke is urgently warranted. the discrimination ability of \mathbf{F} is \mathbf{F} and \mathbf{F} are discriminated. acute phase of stroke is urgently warranted.
Keywords: Ischemic Stroke; Intracerebral Hemorrhage; Diagnosis; Differentiation;

Keywords: Ischemic Stroke; Intracerebral Hemorrhage; Diagnosis; Differentiation;
Blood; Biomarkers; Proteomics. Blood; Biomarkers; Proteomies.
Glossarv:

Glossary:

IS= Ischemic Stroke; ICH= Intracerebral hemorrhage; SDE= Significantly Differentially
Expressed; CT= Computed Tomography; MRI= Magnetic Resonance Imaging; SWATH-
MS= sequential windowed acquisition of all theoretical fragm MRM= Multiple Reaction Monitoring; FDR= False Discovery Rate; PCA= Principal MRM= Multiple Reaction Monitoring; FDR= False Discovery Rate; PCA= Principal
Component Analysis: OR= Odds Ratio: CI= Confidence Interval: ROC= Receiver Component Analysis; OR= Odds Ratio; CI= Confidence Interval; ROC= Receiver Operating Characteristic; AUC= Area Under the Curve; PPV= Positive Predictive Value; NPV= Negative Predictive Value; VIF= Variance Inflation Factor; IDI= Integrated Discrimination Improvement; GO= Gene Ontology; KEGG= Kyoto Encyclopedia of Genes
and Genomes. Bish Characteristic Improvement; Goed Characteristics; Gog Characteristics; Characteristics; Characteristics; God Characteristics; Characteristics; Characteristics; Characteristics; Characteristics; Characteristics; Charac and Genomes.

Introduction
An early diagnosis of stroke and definitive acute treatment is critical in acute stroke care.¹ Early detection of stroke and its subtypes is crucial since the efficacy of reperfusion therapies in ischemic stroke (IS) including intravenous thrombolysis²⁻⁴ and mechanical thrombectomy, 56 is time-dependent. There are several challenges in the diagnosis of IS including poor sensitivity of a computed tomography (CT) scan to diagnose IS in the acute phase, lack of availability of a magnetic resonance imaging (MRI) scan and trained neurologists in resource-limited settings, and expensive cost of imaging equipment's. Therefore, the search for a novel molecular marker for stroke
diagnosis has received growing attention in the last 20 years.⁷⁻⁹ imaging equipments. Therefore, the search for a novel molecular manner for stroke
diagnosis has received growing attention in the last 20 years.⁷⁻⁹
As of 2022, we do not have a functional blood-based stroke biomarker (ei

diagnosis has received growing attention in the last 20 years.7–9
As of 2022, we do not have a functional blood-based stroke bion
or in combination) which can differentiate IS from intracerebra or in combination) which can differentiate IS from intracerebral hemorrhage (ICH) and other similar conditions. We also do not have a point of care test which can strengthen
the stroke diagnosis along with neuroimaging. Most of the studies conducted till date once similar conditions. We also do not have a point of the studies conducted till date
the stroke diagnosis along with neuroimaging. Most of the studies conducted till date
have used the candidate-based immunoassavs with thave used the candidate-based immunoassays with every protein requiring a separate
assay or a multiplex assay approach to determine diagnostic biomarkers for assay or a multiplex assay approach to determine diagnostic biomarkers for differentiating IS from healthy controls, stroke mimics, and ICH within 24 hours. A high-
throughput proteomics approach, on the other hand, can simultaneously quantify many proteins in an exploratory fashion and could potentially be a highly sensitive method to $t_{\rm F}$
proteins in an exploratory fashion and could potentially be a highly sensitive method to
detect diagnostic protein markers in stroke patients at a low cost per sample in a rapid detect diagnostic protein markers in stroke patients at a low cost per sample in a rapid and reproducible manner. Further, recent advancements in label-free quantification of proteins have offered a cost-effective alternative to the labelling methods for discovering protein biomarkers in stroke with subsequent validation in larger cohorts using the targeted proteomics methods. Label-free techniques like sequential windowed acquisition of all theoretical fragment ion mass spectra (SWATH-MS) have been actual fragment is all theoretical fragment ion mass spectra (SWATH-MS) have been mass spectra (SWATH-MS) have been $\mathcal{L}(\mathcal{S})$ have been mass spectra (SWATH-MS) have been mass spectra (SWATH-MS) have been mass spectra

preferred over the control of the commarker discovery.
Diomarker discovery.¹⁰
With the growing need for a blood-based diagnostic biomarker in stroke, it is

biomarker discovery.10
With the growing nee
imperative to utilize imperative to utilize the advantages of the latest high-throughput proteomics approaches and focus on relevant clinical questions for identifying protein biomarkers that have adequate sensitivity and/or specificity to differentiate stroke subtypes in clinical settings. Therefore, we aimed to discover blood-based protein biomarkers to diagnose and differentiate IS from ICH within 24 hours using the untargeted SWATH-MS proteomics approach. We also validated the diagnostic performance of the discovered proteins in a separate cohort of IS, ICH, and stroke mimics using the targeted Multiple Reaction Monitoring (MRM) proteomics approach. $\mathcal{C}(\mathcal{C})$ proteing $\mathcal{C}(\mathcal{C})$ proteing approach.

$\frac{1}{2}$ Methods

Study population and study design

This diagnostic test study was conducted in the Department of Neurology, All India
Institute of Medical Sciences (AIIMS), New Delhi, India in collaboration with Institute of Genomics and Integrative Biology (IGIB), New Delhi, India. From October 2017 to March 2020, we included consecutive stroke patients aged 18 years and above, ischemic or hemorrhagic confirmed by neuroimaging and clinical diagnosis admitted within 24 hours of symptom onset to the neurology wards and/or emergency department of AIIMS, New Delhi. All included patients had clinical signs consistent with the definition of stroke given by the American Heart Association (AHA)/American Stroke Association $f(ASA)$ ¹¹ We also included a group of stroke mimics presenting within 24 hours with stroke-like symptoms. We excluded patients with a previous history of stroke, admission after the 24-hour onset of the qualifying event, cerebral vein thrombosis, admission after the 24-hours on set of the 24-hours of the qualifying event, cerebral vein thrombosis, cerebra
Thrombosis, cerebral vein thrombosis, cerebral vein thrombosis, cerebral vein thrombosis, cerebral vein thrombo chrowilling to provide written informed consent.
The study was approved by the Local Institutional Ethics Committee of AIIMS. New

unwilling to provide written informed consents.
The study was approved by the Local Institu
Delhi (Ref. No. IECPG-395/28.09.2017). We obt Delhi (Ref. No. IECPG-395/28.09.2017). We obtained written informed consent from all the recruited patients or legally authorized representative prior to collecting blood samples and clinical history. The study was divided into two phases: (1) discovery phase and (2) validation phase. The study flow diagram is represented in Figure 1. phase and (2) validation phase. The study flow diagram is represented in Figure 1.

$\ddot{\mathbf{S}}$ Sample size

For the discovery phase, based on the feasibility, budget, and time-frame of the study,
we selected 40 stroke patients comprising of 20 IS and 20 ICH. The literature suggests a
sample size of 10 to 30 for conducting a pilo $\frac{1}{2}$
sample size of 10 to 30 for conducting a pilot/discovery phase study. 12,13
For the validation phase, to achieve a sensitivity and specificity of 90% with 5% margin sample size of 10 to 30 for conducting a phot/discovery phase study.12,13
For the validation phase, to achieve a sensitivity and specificity of 90% v
of error and 5% drop out rate, we estimated a final sample size of 300 c of error and 5% drop out rate, we estimated a final sample size of 300 comprising 150 IS and 150 ICH patients¹⁴ using STATA version 13.0 software.

IS and 150 ICH patients¹⁴ using STATA version 13.0 software.
Blood sample collection Blood sample collection

We collected five ml of peripheral blood samples in serum vacutainer tubes from stroke
patients and mimics within 24-hour onset. For serum collection, it was left standing at room temperature for 30 minutes until clotted. It was then centrifuged at 3000g for 10 minutes, after which the serum was separated into cryovials. Five aliquots of each sample (100 μ l) were prepared and stored at -80 \degree C until further analysis. sample (1000pm) were prepared and stored at -80°C until further and stored at -80°C until further analysis.
.

Sample preparation, Reduction, alkylation, and trypsin digestion

Refer to previously published paper.¹⁵
DISCOVERY PHASE

$\frac{1}{2}$ DISCOVERY PHASE

SWATH-MS data acquisition

Refer to previously published paper.15
Bioinformatic analysis

$\frac{1}{\sqrt{2}}$ Bioinformatic analysis

We used a high-pH fractionated peptide library for human serum proteins (obtained
from SCIEX) comprising 465 proteins. SWATH peaks were extracted using this library in SWATH 2.0 microapp in PeakView 2.2 software (SCIEX), excluding shared peptides. The processing settings for peak extraction were: maximum 10 peptides per protein, 5 transitions per peptide, $>95\%$ peptide confidence threshold, 1% peptide false discovery rate (FDR). XIC extraction window was set to 55 minutes with 75 ppm XIC Width. Data were normalized using total area sum normalization and $log₂$ transformed. Batch correction was performed for removing the non-biological experimental variations and was visualized using the Principal Component Analysis (PCA) plots. Differentially expressed proteins were selected using two criteria: (i) p-value <0.05 and \pm 1.5 fold change cut-offs (>1.5 for upregulated and < 0.67 for downregulated proteins); or (ii) confirmed/tentative selection in the Boruta random forest feature selection method. The STRING 11 online tool¹⁶ was used to create the protein network of the differentially expressed proteins between various conditions. Further, protein-protein interaction network and the functional enrichment analyses were conducted using Cytoscape 3.9.0
software.¹⁷ network and the functional enrichment analyses were conducted using Cytoscape 3.9.00 μ 3.9.00 μ software.¹⁷

VALIDATION PHASE

Differentially expressed proteins obtained in the discovery phase and five proteins
identified in our meta-analysis⁹ were validated using targeted proteomics in the
validation phase. identified in our meta-analysis? were validated using targeted proteomics in the
validation phase.

validation phase.
Pentide selectio $\begin{array}{c} \n\end{array}$ Peptide selection for Multiple Reaction Monitoring (MRM)-based targeted proteomics

Peptide selection was performed using search results from ProteinPilot,¹⁸
PeptideAtlas¹⁹ or in-silico-generated-peptides-of-proteins-using-Expasy-PeptideCutter tool.²⁰ Peptides with $+2$ and $+3$ charges were considered for MRM and for each peptide, 5-6 fragment ions were used for identification. Peptide selection for the list of shortlisted proteins is given in supplementary Table 1.

shortlisted proteins is given in supplementary Table 1.
MRM data acquisition $\frac{1}{2}$ MRM data acquisition

Tryptic peptides obtained after digestion were desalted using reversed-phase Oasis HLB was dried using a vacuum centrifuge, and the peptides were resuspended in 0.1% formic acid at a final concentration of $1\mu g/\mu l$. A heavy labeled peptide for Apo A1 (QGLLPVLESF**K**; **K**=Lysine-13C6,15N2) protein was spiked-in the resolubilized plasma
digest at a final concentration of 1ng/μl. (QGLLI VLESFK; K=Lysine-13C6,15N2) protein was spiked-in the resolubilized plasma
digest at a final concentration of 1ng/µl.
The targeted MRM-MS²¹ analysis of the tryptic peptides was performed on a TSO

یں
The targeted MRM-MS²¹ analysis of th
Altis (Thermo Fisher. San Iose. CA). Th Altis (Thermo Fisher, San Jose, CA). The instrument was equipped with an H-ESI ion source. A spray voltage of 3.5 keV was used with a heated ion transfer tube set at a temperature of 325° C. Chromatographic separations of peptides were performed on Vanquish UHPLC system (Thermo Fisher, San Jose, CA). Vanquish UHPLC system (Thermo Fisher, San Jose, CA).

Ten μl sample was injected and peptides were loaded on an ACQUITY UPLC BEH C18
column (130Å, 1.7 μm, 2.1 mm X 100 mm, Waters) from a cooled (4°C) autosampler and separated with a linear gradient of water (buffer A) and acetonitrile (buffer B), containing 0.1% formic acid, at a flow rate of 300μ *l*/minute in 30 minutes gradient run. containing 0.1% formic acid, at a flow rate of 300µl_m, minute in 30 minutes gradient run.
Statistical analysis

Statistical analysis

Skyline version 21.1 was used to analyze the MRM data.²² The area for each peptide was
spike-in normalized using a heavy labeled peptide for Apo A1 protein and then \log_2 transformed. The random forest-based imputation was performed for peptides with 10% missing values.²³ The normality of the data was assessed using the Shapiro-Wilk test. <10% missing values.23 The normality of the data was assessed using the Shapiro-Wilk

The
Accu Accuracy (STARD) guidelines.²⁴ For each comparison, IS was taken as the endpoint and
univariable logistic regression analysis was conducted using odds ratio (OR) and 95% Accuracy (STARD) guidelines.²⁴ For each comparison, is was taken as the endpoint and
univariable logistic regression analysis was conducted using odds ratio (OR) and 95%
confidence interval (CI). Receiver operating chara univariable localistic regression and confidence interval (CI). Receiver operating characteristic (ROC) curve analyses were
Derformed for biomarkers differentiating IS from ICH and stroke mimics. The optimal performed for biomarkers differentiating IS from ICH and stroke mimics. The optimal cut-off points were determined using the Youden Index. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of each biomarker were determined. Since the aim of this study was to detect and diagnose IS, cut-offs for each biomarker were selected having the highest sensitivity values to detect IS and to
rule out ICH or mimics with the best available specificity values. $\frac{1}{2}$
rule out ICH or mimics with the best available specificity values.
Prediction models were develoned to determine the accuracy and nrecision of nrotein

rule out ICH or minister with the best available specificity values.
Prediction models were developed to determine the accuracy a
biomarkers and their discrimination ability was evaluated usir biomarkers and their discrimination ability was evaluated using area under the curve $(AUC)/c$ -statistic. The clinical variables with p-value <0.1 in the univariable analysis along with demographic variables like age and sex, were included in a backward along with demographic variables like age and sex, were included in a backward in a backward in a backward in
In a backward in a backwar
I

stepwise multivariable logistic regression analysis. Afterward, biomarkers were added increase in the AUC/c-statistic were retained in the model. Another prediction model was developed to determine the diagnostic potential of biomarkers alone in differentiating IS. For each prediction model, the degree of multicollinearity was tested using the variance inflation factor (VIF) and predictors with VIF value >2.5 were removed from the final model. The discrimination ability (AUC) between various prediction models was compared and quantitatively assessed using the Hanley-McNeil test p-value.²⁵ At different pre-test probabilities of the disease, the corresponding posttest probability, and the multi-level likelihood ratio were determined. The integrated discrimination improvement (IDI) index was calculated to assess the added value of the biomarkers to the clinical predictive models.^{26,27} The goodness-of-fit between the two
hierarchical prediction models was evaluated using the Likelihood Ratio (LR) test based biomarkers to the clinical predictive models.^{26,27} The goodness-of-fit between the two
hierarchical prediction models was evaluated using the Likelihood Ratio (LR) test based
on the ratio of their likelihoods.²⁸ The se on the ratio of their likelihoods. 28 The selection of the best prediction model was done
using Akaike's Information Criteria (AIC) 29 and Bavesian Information Criteria (BIC). 30 using Akaike's Information Criteria (AIC)²⁹ and Bayesian Information Criteria (BIC).³⁰ The statistical analyses were conducted in R version 3.6.2 and STATA version 13.1. The statistical analyses were conducted in R version 3.6.2 and 3.1.1.1.1.1.1.1.1.1.1.1.
Data availability

Data availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE³¹ partner repository with the dataset identifier PXD032917. Consortium via the PRIDE³¹ partner repository with the dataset identifier PXD032917.
Results

$\begin{array}{c} \n\end{array}$

Results
Results
We enro Results from the Discovery Phase

We enrolled 40 patients in the discovery phase: 20 IS and 20 ICH patients recruited
within 24 hours. Between IS and ICH cases, there was no significant difference in the with 24 hours. Between IS and ICH cases, there was no significant difference in the was no significant differen

mean age (p=0.12) and mean blood sampling time from symptom onset (p=0.86). The
baseline characteristics of the patients are given in supplementary Table 2. Serum proteomic profiles were compared between 20 IS and 20 ICH cases using the SWATH-MS approach. We quantified 375 proteins at 1% peptide FDR between IS and ICH. The total ion chromatogram and the PCA plots depicting batch variations are given
in supplementary figure 1 and supplementary figure 2. $\frac{1}{\sqrt{2}}$
In supplementary figure 1 and supplementary figure 2.
We identified 14 differentially expressed proteins using the fold change and p-value

 $\begin{array}{c} \bullet \end{array}$
We identified 14 differentially expressed proteins us:
criteria. Three proteins were upregulated. while 11 wei criteria. Three proteins were upregulated, while 11 were downregulated in IS compared to ICH (Figure 2a). We further identified 11 confirmed/tentative features between IS and ICH using the Boruta random forest method (Figure 2b and supplementary Table 3). Five proteins (UniProt IDs: P01023, P01833, P01764, P19652, and P02654) were common using both protein selection criteria. Therefore, after combining the distinctly expressed proteins using both criteria, 20 differentially expressed proteins were identified between IS and ICH within 24 hours (Table 1). A heatmap of these 20 proteins
is depicted in Figure 2c. is depicted in Figure 2c.
Interaction network analysis observed that 15 proteins formed a highly connected

is dependence gave 20
Interaction network an
network showing molec network showing molecular interactions with other proteins (Figure 2d). APOH had the highest degree of interaction with other proteins followed by APOA1, A2M, and HP. In our network, 10 protein-protein interactions had an interaction score of >0.90 . Functional enrichment analysis identified molecular pathways/processes involving blood microparticles, extracellular space, lipoprotein particles, cholesterol metabolism, platelet degranulation, and post translational protein phosphorylation that were significantly different between IS and ICH (supplementary Table 4). significantly different between IS and ICH (supplementary Table 4). The contract of the supplementary Table 4, $\frac{1}{2}$.

Results from the Validation Phase

We included 306 cases in the validation phase; 300 stroke patients (150 IS and 150 ICH)
and 6 stroke mimics within 24 hours. The mean age of IS, ICH, and stroke mimics were 54.59 ± 15.54 , 55.30 ± 12.72 , and 47.83 ± 18.25 years, respectively. IS, ICH, and stroke mimics consisted of 64.67%, 65.33%, and 66.67% males. The mean blood sampling time (in hours) from symptom onset was 15.29 ± 5.55 in IS, 14.97 ± 6.55 in ICH, and 8.75 \pm 5.07
in stroke mimics. The 6 stroke mimics included natients suffering from hynoglycaemia (in hours) from symptom onset was 15.29±5.55 in IS, 14.97±6.55 in ICH, and 8.75±5.07
in stroke mimics. The 6 stroke mimics included patients suffering from hypoglycaemia
(2) vertigo (2) syncone (1) and seizure (1) (supplem in stroke mimics. The 6 stroke mimics included patients suffering from hypoglycaemia
(2), vertigo (2), syncope (1), and seizure (1) (supplementary Table 5 and
supplementary Table 6). $\sum_{i=1}^{n}$ (1), and set $\sum_{i=1}^{n}$ (1), and set $\sum_{i=1}^{n}$ and supplementary Table 6).
We validated 20 differentially expressed proteins identified in the discovery phase and

rr
We validated 20 differen
five proteins (GFAP. BN five proteins (GFAP, BNP, D-dimer, MMP-9, and UCH-L1) identified in our published meta-analysis.⁹ While selecting the peptides of interest for MRM, unique peptides for two proteins (UniProt IDs: $P01764$ and P01601) could not be determined, while the unique peptide (TDISMSDFENSR) for PIGR protein (UniProt ID: P01833) was not detectable in any sample, thus they were excluded from the final analysis. Therefore, 22 proteins (17 from discovery phase and five from meta-analysis) were selected in our validation phase. One unique peptide per protein was used for quantification. The final list of unique peptides and quantifier fragment ion for each protein is given in
supplementary Table 7. $\mathcal{L}_{\text{supplementary Table 7}}$.

$\frac{1}{2}$ supplementary $\frac{1}{2}$ and $\$ Univariable analysis in the Validation Phase

In the univariable analysis, the protein concentration of 15 out of 22 biomarkers were
different between IS and ICH (p-value <0.1) (supplementary Table 8). The diagnostic characteristics for the 15 categorized biomarkers are given in Table 2. In a subgroup analysis conducted within 6 hours, nine of 22 biomarkers significantly differentiated 12 analysis conducted within 6 hours, nine of 22 biomarkers significantly differentiated 12 \pm IS from 26 ICH cases (supplementary Table 9 and supplementary Table 10). In a
secondary analysis, only three biomarkers differentiated IS from stroke mimics within
24 hours (supplementary Table 11). secondary analysis, only three biomarkers differentiated IS from stroke minicial minics within
24 hours (supplementary Table 11).

$\frac{1}{2}$ Multivariable regression analysis $\frac{1}{1}$ Multivariable regression analysis in the validation phase

Clinical model

Five clinical variables including sex (OR 2.12; 95%CI 1.12-4.02), hypertension (OR 0.40;
95%CI 0.23-0.70), atrial fibrillation (OR 9.13; 95%CI 2.01-41.57), current smoking (OR 3.19; 95%CI 1.70-5.96), and NIHSS score at admission (OR 0.87; 95%CI 0.84-0.90) were independent predictors of IS (AUC/c-statistic of 81%) (Table 3).

independent predictors of IS (AUC/C-statistic of 81%) (Table 3).
Biomarker model $\frac{1}{1}$ Biomarker model

eight protein biomarker including GFAP (OR 0.17) of the OR 9.28; 95%CI 0.06-0.42), APO-C1 (OR 6.56; 95%CI 3.20-13.45), APO-A1 (OR 0.28; 95%CI 0.09-
0.81), Hantoglobin (OR 2.88; 95%CI 1.26-6.58), UCH-L1 (OR 0.35; 95%CI 0.14 95%CI 0.06-0.42), APO-C1 (OR 6.56; 95%CI 3.20-13.45), APO-A1 (OR 0.28; 95%CI 0.09- 0.81 (OR 0.38; 95%CI 0.15-0.95), and Serotransferrin (OR 4.40; 95%CI 1.30-14.85) were independent predictors of IS (AUC/c-statistic of 88%) (Table 3).

were independent predictors of the ₍₂₂₂₃₎ (Table 3).
Combined model (clinical variables + protein biomarkers) $\frac{1}{1}$ Combined model (clinical variables + protein biomarkers)

Proteins that were significant in the biomarker model were incrementally added to the
clinical model. In the combined prediction model, four clinical variables including hypertension (OR 0.38; 95%CI 0.19-0.76), atrial fibrillation (OR 21.92; 95%CI 3.17-
151.35), current smoking (OR 3.00; 95%CI 1.37-6.55), and NIHSS score at admission hypertension (OR 0.98; 95%CI 0.84-0.91), and three protein biomarkers including GFAP (OR 0.04;
TOR 0.87: 95%CI 0.84-0.91), and three protein biomarkers including GFAP (OR 0.04; 151.359, 201.359, contracting (OR 0.87; 95%CI 0.84-0.91), and three protein biomarkers including GFAP (OR 0.04; $(3.87, 0.97, 0.97, 0.97, 0.97, 0.97)$ and three proteins including GFAP (OR 0.04; $\frac{1}{2}$), and the protein biomarkers including GFAP (OR 0.04; $\frac{1}{2}$) 95%CI 0.02-0.11), MMP-9 (OR 0.09; 95%CI 0.03-0.28), and APO-C1 (OR 5.76; 95%CI
2.66-12.47) were independent predictors of IS (AUC/c-statistic of 92%) (Table 3).

Comparing the diagnostic performance of prediction models

We compared the ROC curves of three prediction models using the Hanley and McNeil test. We observed that the combined model had significantly higher AUC compared to
biomarker model (p=0.036) and clinical model (p<0.0001) (Figure 3). t
biomarker model (p=0.036) and clinical model (p<0.0001) (Figure 3).
The IDI index suggested that combined model increased the discrimination ability by

 $\frac{1}{2}$
The IDI index suggested that combined model increased the discrim
13% (p<0.001) compared to biomarker model and by 26% (p<0.0 13% (p<0.001) compared to biomarker model and by 26% (p<0.001) compared to
clinical model. $\frac{1}{2}$ clinical model.

The goodness-of-fit between the clinical and combined models (hierarchical models)

rmmanus.
The goodness-
was compared y
was compared using the likelihood ratio test. The addition of three protein biomarkers
(GFAP. MMP-9. and APO-C1) to the clinical variables significantly increased the was compared using the limit of the clinical variables significantly increased the direction of the clinical variables significantly increased the likelihood ratio by 102.74 (p<0.001). Further, combined model including cl likelihood ratio by 102.74 ($p<0.001$). Further, combined model including clinical and biomarker variables, had the least AIC and BIC values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit $\ddot{}$ Comparison between prediction models at different pre-test probabilities

Combined model including clinical variables and protein biomarkers (GFAP, MMP-9,
APO-C1), improved the pre-test probability of diagnosing an IS from 30%, 50%, and 70% to a post-test probability of 57%, 82%, and 95%, respectively. Combined model had the best sensitivity, specificity, and likelihood ratios at all the three pre-test probability cut-offs compared to clinical and biomarker models. At a pre-test probability of 30%, combined model had the highest NPV of 94% to rule out ICH (Table
4). probability of 30%, combined model in algorithm NPV of 94% to rule out ICH (Table
4). 4).

Discussion
In the discovery phase, our study identified 20 differentially expressed proteins between IS and ICH. Of these 20 proteins, in the validation phase, we identified three biomarkers (GFAP, MMP9, APOC1) that independently differentiated IS from ICH in multivariable analyses. When these three biomarkers were added to the prediction models containing clinical variables, they significantly improved the discrimination ability to detect IS. GFAP and MMP9 further differentiated the two stroke subtypes in a
subgroup analysis within 6 hours. In a secondary analysis, we identified three ability to detect IS-12. Given the Californian MMP9 further the Secondary of the subgroup analysis, we identified three
biomarkers (APO-L1, BNP, FBXW5) that differentiated IS from stroke mimics. To the subserved in the subgroup of the biomarkers (APO-L1, BNP, FBXW5) that differentiated IS from stroke mimics. To the
best of our knowledge, this is the first study that has utilized the discovery-based labelbest of our knowledge, this is the first study that has utilized the discovery-based label-
free SWATH-MS proteomics and targeted MRM proteomics to identify and validate differentially expressed protein biomarkers in the blood of patients with IS and ICH free SWATH-MS protein system in the blood of patients with IS and ICH
Within 24 hours of symptom onset. differentially expressed protein biomarkers in the blood of patients with IS and ICH
within 24 hours of symptom onset. within 24 hours of symptom onset.
Our findings highlight the importance of a panel-based approach in diagnostic

 $\frac{1}{1}$ biomarker research in stroke. Our study observed that a combined panel of biomarkers and clinical variables detected IS from ICH with an accuracy of 92%. Only a few studies in the past have adopted the panel-based approach. The Stroke-Chip study in 2017^{32} included a panel of clinical variables and biomarkers in which only NT-proBNP independently differentiated IS from ICH with an accuracy of 75.7%. Earlier, Montaner *et al.* in 2012³³ observed that in a combined panel, S100B and RAGE independently differentiated IS from ICH with an improved accuracy of 84% Thus, future studies must focus on testing the diagnostic potential of their biomarkers in multivariable prediction models to identify independent biomarkers for IS diagnosis. models to identify independent biomarkers for IS diagnosis.
The independent biomarkers for IS diagnosis.

For the first time our study used a label-free proteomics approach to detect the levels of
proteins identified in the literature such as GFAP, MMP9, BNP, D-dimer, and UCH-L1 in stroke patients. We focussed on finding a combination of biomarkers with/without clinical variables which can detect IS with high sensitivity and a high NPV to rule out ICH. The poor specificity values observed in most of the biomarkers when analyzed alone, were improved significantly when combined in a panel.

Our network analysis identified an interaction network of 15 proteins that was highly $\ddot{}$ connected. The most common significant pathways underlying the proteins differentiating IS from ICH included cholesterol metabolism and lipid-related processes, platelet degranulation, and pathways related to extracellular space and matrix.

Thus far, no proteomics study conducted in stroke has identified biomarkers within the $\frac{1}{2}$ 24-hour time window. In a recent study, Malicek et al. 2021³⁴ used a similar discoverybased label-free proteomics approach and identified nine proteins in a small sample of 3 IS and 4 ICH patients. They collected blood samples between 1 to 15 days and lacked a validation phase. Of these nine proteins, serum amyloid P-component was also differentially expressed in our discover phase. Another study by Zhang *et al*. 2021³⁵
collected serum within five days and identified two metabolic biomarkers between IS differentially expressed in our discover phase. Another study by Zhang *et ul*. 2021³³
collected serum within five days and identified two metabolic biomarkers between IS
and ICH using targeted metabolomics. Lopez *et al* constant serving collecting services and the instance of the services of the service of the series and ICH using targeted metabolomics. Lopez *et al*. (2012)³⁶ used targeted proteomics
and identified a combination of APO and identified a combination of APO-CIII and APO-AI that differentiated IS from ICH with an AUC of 0.92. In our discovery phase, we also observed that APO-AI was significantly downregulated in IS by 0.61 fold compared to ICH. significantly downregulated in IS by 0.61-fold compared to ICH.

Several studies in the past have used immunoassays to identify candidate protein
biomarkers for differentiating IS from ICH. GFAP is the most extensively studied protein and several systematic reviews and meta-analyses, $37-40$ including those published by our group^{8,9,41} also reiterate our findings that GFAP efficiently differentiates the two stroke subtypes with high sensitivity and/or specificity within 24 as well as 6 hours. With regards to MMP9, our findings are in line with several other published studies 33.42 - 44 and meta-analysis,⁹ that observed that MMP-9 has significantly lower levels in IS than ICH and efficiently differentiates the two stroke subtypes within 24 hours.

Previous studies have had contradictory results regarding the APO-C1 levels in IS and $\frac{1}{1}$ ICH patients. In our study, we detected higher levels of APO-C1 in IS than ICH. The increased levels of APO-C1 during acute IS might be related to its key role in lipid
metabolism, also observed in the pathway analysis in our study. One study by Allard *et* increased to the Freedom and the pathway analysis in our study. One study by Allard *et*
al. (2004)⁴⁵ corroborates our findings as they observed higher levels of APO-C1 in IS metabolism, also observed in the pathway analysis in our study. One study by Allard et
al. (2004)⁴⁵ corroborates our findings as they observed higher levels of APO-C1 in IS
than ICH. However, a study by Walsh *et al.* (2 than ICH. However, a study by Walsh et al. $(2016)^{46}$ observed that in a small sample of 14 IS and 23 ICH cases, the median APO-CI levels were slightly lower in IS compared to ICH. Therefore, more adequately powered studies are required to confirm the levels of
APO-C1 in stroke subtypes. ICH. Therefore, more adequately powered studies are required to confirm the levels of $\frac{1}{2}$

$\overline{}$
Strengths of our study $\ddot{}$ Strengths of our study

This study provides crucial insights into the pathophysiology of IS and ICH in acute
stages. We validated the diagnostic potential of discovered biomarkers in a large cohort of patients using a high-throughput proteomics approach. Our study was conducted in resource-limited settings wherein there is an urgent need for an alternative approach. toward rapid stroke diagnosis. Our study analyzed the individual protein profile of each toward rapid stroke diagnosis. Our study analyzed the individual protein profile of each

patient using proteomics in both discovery and validation phases without pooling any
sample. Since, pooled samples do not reflect the diseased/non-diseased condition of a single person and may produce false-positive or false-negative results.

$\begin{array}{c} \mathbf{S} \end{array}$ is a person and may produce false-positive results. The study results is a person of the study $\frac{1}{1}$ Limitations of the study

Certain inherent limitations associated with our study must be kept in mind when
interpreting its results. Firstly, the serum samples were obtained only from the Indian population; thus, further studies conducted in ethnically diverse populations are required to validate the generalizability of the biomarkers identified in our study Secondly, relative quantification of proteins was done in the validation phase. To determine the biomarker levels with absolute quantification, future studies must be conducted on these biomarkers using either labelled peptide-based targeted proteomics or standard immunoassays. Lastly, the number of stroke mimics included in this study were very less, therefore, findings were only exploratory. were very less, therefore, $\frac{1}{2}$ is the contract on $\frac{1}{2}$. Finding were only explorations were only explorations were only the contract on $\frac{1}{2}$

Future directions

The literature on proteomics studies for diagnostic biomarkers in stroke is mainly
limited to the discovery phase, while the validation phase is lacking. Therefore, studies must look to validate their discovered biomarkers in a large independent cohort using. either standard immunoassays or targeted proteomics approaches using MRM. Since stroke is a multifactorial disorder, a single biomarker approach might not be appropriate, and instead studies must look for a panel of biomarkers that may increase the overall sensitivity and specificity of the diagnosis. The ability of the biomarkers to
independently diagnose IS must be evaluated in multivariable regression models the overally diagnose is must be evaluated in multivariable regression models
the diagnosisting of potential clinical predictors along with independent protein biomarkers. independent generating and greater in multivariable in multivariable regression models. consisting of potential predictors along with independent predictors and predictors along with independent pro
The construction biomarkers. The construction biomarkers. The construction of the construction of the construct Studies should also examine the improvement in the discrimination ability and the
incremental value of any biomarker over clinical variables using various statistical approaches. Future studies should utilize the advanced label-free proteomics technology for biomarker research in stroke. They require a minimal sample volume at a low cost per sample. This approach would be convenient for studies investigating a panel of biomarkers. Studies must avoid pooling of samples when conducting their proteomics experiments to avoid false positive/false negative results. proteimics experiments to avoid false positive/false in general contracts.
Conclusion

$\ddot{}$

Conclusion
Our study identified 20 differentially expressed proteins between IS and ICH in the discovery phase using SWATH-MS proteomics with a strong interaction network for 15 proteins. The validation phase highlighted the potential of 15 biomarker candidates in differentiating IS from ICH within 24 hours. The prediction model including three protein biomarkers (GFAP, MMP9, and APOC1) and clinical variables, had the best discrimination ability and increased the post-test probability of detecting IS with high sensitivity, specificity, and likelihood ratios. Protein biomarkers along with clinical predictors significantly improved the discrimination ability of the model in differentiating IS from ICH within 24 hours. Our results must be validated in other populations using absolute quantification to confirm the generalizability of our findings and the diagnostic performance of the identified biomarkers.

$\begin{array}{c} \bullet \end{array}$ and the diagnostic performance of the identified biomarkers. $\overline{1}$ Contributors

DV conceptualized the idea of this research topic, helped design the clinical
methodology, supervised each step of execution of this study. SM primarily conducted each step of this study ranging from blood sample collection, processing, proteomics each step of this step of this step of this study ranging from blood sample collection, protein, protein,

experimentation, statistical and proteomic data analysis, results interpretation, and
manuscript writing. SSG supervised the proteomics experimentation and its data analysis. SM and PS conducted the proteomics experiments and data analysis. MK, ZR, DB, and RC contributed in conducting the proteomics experimentations in the study. PT and MN contributed in patient sample collection and processing. PK and AK helped in statistical data analysis. DV, PA, AKS, AKP, DM, and KP aided in patient recruitment for this study. All authors contributed to, reviewed, and approved the final draft of the
paper. this study. All authors contributed to, reviewed, and approved the final draft of the
paper.

Disclosures $\begin{array}{c} \n\cdot \\
\cdot\n\end{array}$

The authors report no disclosures relevant to the manuscript.

Γ $\frac{1}{2}$ Acknowledgement

 $\begin{array}{l} \text{Government of India.} \end{array}$

Government of India.
Study Funding $\ddot{}$ Study Funding

 $T_{\rm 5}$ study was supported in part by the AIIMS Interaction of \sim $\frac{1}{2}$ and $\frac{1}{2}$

$72/22/22/22$
Ethics Approval Ethics Approval

The study was approved by the local institutional ethics committee of AIIMS, New Delhi
(Ref. No. IECPG-395/28.09.2017). $\mathcal{L} = \frac{1}{\sqrt{2}}$

References

- 1. There is, 2011 Theory, 2011 of all pathway Design for the care of the in the Branch Branch Branch Branch
Branch Stroke 2020; 51: 3452–3460.
2. IST-3 collaborative group, Sandercock P, Wardlaw JM, et al. The benefits and
- Era of Endovascular Thromas Critical Overview of planned and Lite
Stroke 2020; 51: 3452–3460.
IST-3 collaborative group, Sandercock P, Wardlaw JM, et al. The benefits and harr
of intravenous thrombolysis with recombinant t *Stroke 2020, 51: 3452–3460.*
IST-3 collaborative group, Sar
of intravenous thrombolysis v
6 h of acute ischaemic stroke 2. IST-3 collaborative group, Sandercritics, Wardlaw JSS, Collaborative entired and hardlands
of intravenous thrombolysis with recombinant tissue plasminogen activator within
6 h of acute ischaemic stroke (the third intern 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a
randomised controlled trial. *Lancet* 2012; 379: 2352–2363.
Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours aft randomised controlled trial. *Lancet* 2012; 379: 2352–2363.
3. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after
- acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
- 4. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute acute ischemic stroke. N *Engr J Med 2000, 339*: 1317–1329.
Emberson J, Lees KR, Lyden P, et al. Effect of treatment dela
severity on the effects of intravenous thrombolysis with alte
ischaemic stroke: a meta-analysis of i everity on the effects of intravenous thrombolysis with alteplase for acute
ischaemic stroke: a meta-analysis of individual patient data from randomised
Lancet 2014; 384: 1929–1935. schaemic stroke: a meta-analysis of individual patient data from randomise
Lancet 2014; 384: 1929–1935.
Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours aft
- is character 2014; 384: 1929–1935.
Lancet 2014; 384: 1929–1935.
Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after
Stroke with a Mismatch between Deficit and Infarct. *N Engl J Med* 2018; 378: 11–2 Lancet 2014, 304: 1929–1935.
Nogueira RG, Jadhav AP, Hausse
Stroke with a Mismatch betwee
- 5. Stroke with a Mismatch between Deficit and Infarct. N Engl J Med 2018; 378: 1
6. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours
Selection by Perfusion Imaging. N Engl J Med 2018; 378: 708–7 Stroke with a Mismatch between Deficit and Imarct. N Engry Med 2010, 378: 11–21.
Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with
Selection by Perfusion Imaging. N *Engl J Med* 2018; 378: 7
- 6. Selection by Perfusion Imaging. *N Engl J Med* 2018; 378: 708–718
7. Whiteley W, Tseng M-C, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. *Stroke* 2008; 39: 2902–2909.
8. Misra S, Kumar A, Kumar P, et al. Blood-based protein biomarkers for stroke
- 1. Whiteley W, Theogene B, Sanders Core (Stroke 2008; 39: 2902–2909.

8. Misra S, Kumar A, Kumar P, et al. Blood-based protein biomarkers for stroke

differentiation: A systematic review. Proteomics Clin Appl; 11. Epub ahe ischemic stroke: a systematic review. *Stroke* 2008; 39: 2902–2909.
Misra S, Kumar A, Kumar P, et al. Blood-based protein biomarkers f
differentiation: A systematic review. *Proteomics Clin Appl*; 11. Epub
September 2017. 8. Misra S, Montaners, American S, Chemin Proteomics Clin Appl; 11. Epub ahead of
September 2017. DOI: 10.1002/prca.201700007.
9. Misra S, Montaner J, Ramiro L, et al. Blood biomarkers for the diagnosis and
- September 2017. DOI: 10.1002/prca.201700007.
Misra S, Montaner J, Ramiro L, et al. Blood biomarkers for the diagnosis and
differentiation of stroke: A systematic review and meta-analysis. *Int J Stroke* 2020; 9. Misra S, Montaner J, Ramiro L, et al. Blood biomarkers for the diagnosis and differentiation of stroke: A systematic review and meta-analysis. *Int J Stroke*
15: 704–721. differentiation of stroke: A systematic review and meta-analysis. *Int J Stroke*
15: 704–721.
10. Jylhä A, Nättinen J, Aapola U, et al. Comparison of iTRAQ and SWATH in a clii
- differentiation of stroke: A systematic review and meta-analysis. *Int J Stroke 2020*;
15: 704–721.
Jylhä A, Nättinen J, Aapola U, et al. Comparison of iTRAQ and SWATH in a clinical
study with multiple time points. *Clin P* Jylhä A, Nättir
study with mı
- tudy with multiple time points. *Clin Proteomics* 2018; 15: 24.
11. RI S, Se K, Jp B, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart study with multiple time points. C*lin Proteomics 2018*, 15: 24.
Rl S, Se K, Jp B, et al. An updated definition of stroke for the 21
statement for healthcare professionals from the American Hea
Association/American Stroke statement for healthcare professionals from the American Heart
Association/American Stroke Association. *Stroke*; 44. Epub ahead of print July 2013.
DOI: 10.1161/STR.0b013e318296aeca. Association/American Stroke Association. *Stroke*; 44. Epub ahead
DOI: 10.1161/STR.0b013e318296aeca.
Wilmoth GH. Handbook in research and evaluation, Second Editio
- Association/American Stroke Association. *Stroke*, 44. Epub ahead or print July 2013.
DOI: 10.1161/STR.0b013e318296aeca.
Wilmoth GH. Handbook in research and evaluation, Second Edition Stephen Isaac
and William B. Michael Wilmoth GH. Handbook in research and
and William B. Michael San Diego, CA: E.
Studies 1982; 7: 124–126. and William B. Michael San Diego, CA: EDITS Pubs., 1981. Group & Organization
Studies 1982; 7: 124–126.
- and William B. Michael San Diego, CA: EDITS I dbs., 1981. Group & Organization
Studies 1982; 7: 124–126.
Julious SA. Sample size of 12 per group rule of thumb for a pilot study.
Pharmaceutical Statistics 2005; 4: 287–2 Studies 1982; 7: 124–126.
Julious SA. Sample size of 1
Pharmaceutical Statistics 2 Pharmaceutical Statistics 2005; 4: 287-291. P harmaceutical Statistics 2005; 4: 287–291.

- 14. Prasad K. Sample size calculation with simple math for clinical researchers. *Natl Med*
J *India* 2020; 33: 372–374.
15. Misra S, Singh P, Nath M, et al. Blood-based protein biomarkers for the diagnosis of
- J India 2020; 33: 372–374.
Misra S, Singh P, Nath M, et
acute stroke: A discovery-b
2022; 13: 989856. acute stroke: A discovery-based SWATH-MS proteomic approach. *Front Neurol*
2022; 13: 989856.
16. Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021:
- 2022; 13: 989856.
Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021:
customizable protein-protein networks, and functional characterization of user-16. Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021:
customizable protein-protein networks, and functional characterization of u
uploaded gene/measurement sets. *Nucleic Acids Res* 2021; 49: D605–D612 16. Semining 16. Samuel 11, Philip 119, Philip 118. Shamilt also the customizable protein-protein networks, and functional characterization
17. Shannon P, Markiel A, Ozier 0, et al. Cytoscape: a software environment
- integrated models of biomolecular interaction networks. *Genome Res* 2003; 13:
2498–2504.
18. Seymour SL, Hunter CL. ProteinPilotTM Software overview. 5. uploaded gene/measurement sets. Nucleic Acids Res 2021, 49: D605–D612.
Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for
integrated models of biomolecular interaction networks. *Genome Res* 2003;
 integrated models of biomolecular interaction networks. *Genome Res 2003*, 13:
2498–2504.
Seymour SL, Hunter CL. ProteinPilotTM Software overview. 5.
-
- 2009
Seymour SL,
Desiere F, De 19. Desiere F, Deutsch EW, King NL, et al. The PeptideAtlas project. Nucleic Acids Res
2006; 34: D655-658.
- 20. Wilkins MR, Gasteiger E, Bairoch A, et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 1999; 112: 531-552.
- 20. William March, Gasteiger E, Bairoch Mol. Biol. 1999; 112: 531–552.
21. Zhang H, Liu Q, Zimmerman LJ, et al. Methods for peptide and protein quantitation
by liquid chromatography-multiple reaction monitoring mass spectr the Ext Asy server. Methods Mor Bior 1999; 112: 531–552.
Zhang H, Liu Q, Zimmerman LJ, et al. Methods for peptide a
by liquid chromatography-multiple reaction monitoring m
Proteomics 2011; 10: M110.006593. 22. MacLean B, Tomazela DM, Shulman N, et al. Skyline: an open source document
22. MacLean B, Tomazela DM, Shulman N, et al. Skyline: an open source document
- by infuld chromatography-multiple reaction monitoring mass spectrometry. Mor cell
Proteomics 2011; 10: M110.006593.
MacLean B, Tomazela DM, Shulman N, et al. Skyline: an open source document
editor for creating and analyzi Proteomics 2011, 10: M110.000593.
MacLean B, Tomazela DM, Shulman M
editor for creating and analyzing targ
2010; 26: 966–968. 22. Machines B, Tomazon B, Tomania D, Company, Tomani_a D, The Superiments. *Bioinforma*
2010; 26: 966–968.
23. Stekhoven DJ, Bühlmann P. MissForest-non-parametric missing value imputat
- editor for creating and analyzing targeted proteomics experiments. *Bioinformatics*
2010; 26: 966–968.
Stekhoven DJ, Bühlmann P. MissForest--non-parametric missing value imputation
for mixed-type data. *Bioinformatics* 201 2010; 26: 966–968.
- 22. Stephen DJ, Buhlmann President Dividen President Divident Inc.
23. Stephen Dividends 2012; 28: 112–118.
24. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential
28. Stephen Dividends items for mixed-type data. *Biomformatics 2012, 28: 112–116.*
Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: ar
items for reporting diagnostic accuracy studies. *BMJ* 201
- items for reporting diagnostic accuracy studies. *BMJ* 2015; 351: h5527.
25. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating
25. Hanley JA, McNeil BJ. A method of comparing the areas under re items for reporting diagnostic accuracy studies. BMJ 2015, 551: h5527.
Hanley JA, McNeil BJ. A method of comparing the areas under receiver o
characteristic curves derived from the same cases. *Radiology* 1983; 148
- 25. Hanley Ja, Hanley J, Hanley Hanley Hanley Hanley Hanley Hanley Hanley Pramis
characteristic curves derived from the same cases. Radiology 1983; 148: 839–84:
26. Pencina MJ, D'Agostino RB, D'Agostino RB, et al. Evaluati characteristic curves derived from the same cases. Rudiology 1983, 148: 839–843.
Pencina MJ, D'Agostino RB, D'Agostino RB, et al. Evaluating the added predictive
ability of a new marker: from area under the ROC curve to re 26. Pencina M_{J,} Dength MJ, Dength MJ, Dength MJ, Dength Manual States and added provided beyond. *Stat Med* 2008; 27: 157–172; discussion 207-212.
27. Pickering JW, Endre ZH. New metrics for assessing diagnostic potentia
- beyond. *Stat Med* 2008; 27: 157–172; discussion 207-212.
Pickering JW, Endre ZH. New metrics for assessing diagnostic potential of cand
biomarkers. *Clin J Am Soc Nephrol* 2012; 7: 1355–1364. beyond. Stat Med 2000, 27: 157–172, discussion 207–212.
Pickering JW, Endre ZH. New metrics for assessing diagnos
biomarkers. *Clin J Am Soc Nephrol* 2012; 7: 1355–1364.
- 28. Dumonceaux R, Antle CE, Haas G. Likelihood Ratio Test for Discrimination between
28. Dumonceaux R, Antle CE, Haas G. Likelihood Ratio Test for Discrimination between
1973; 15: biomarkers. C*lin J Am Soc Nephrol* 2012; 7: 1333–1364.
Dumonceaux R, Antle CE, Haas G. Likelihood Ratio Test
Two Models with Unknown Location and Scale Paramet
19–27. Two Models with Unknown Location and Scale Parameters. *Technometrics* 1973; 15:
19–27. Two Models with Unknown Location and Scale Parameters. Technometrics 1973; 15:
19–27.

-
- 29. Akaike H. A New Look at the Bayes Procedure. *Biometrika* 1978; 65: 53–59.
30. Gideon Schwarz. Estimating the Dimension of a Model. *The Annals of Statistics* 1978;
6: 461–464.
- 30. Gideon Schwarz. Estimating the Dimension of a Model. The Annuls of Statistics 1970;
6: 461–464.
31. Perez-Riverol Y, Csordas A, Bai J, et al. The PRIDE database and related tools and
resources in 2019: improving suppor -
Perez-Riverd
resources in
2019; 47: D4 resources in 2019: improving support for quantification data. *Nucleic Acids Res*
2019; 47: D442–D450.
32. Bustamante A, López-Cancio E, Pich S, et al. Blood Biomarkers for the Early
- resources in 2019: improving support for quantification data. Nucleic Acias Res
2019; 47: D442–D450.
Bustamante A, López-Cancio E, Pich S, et al. Blood Biomarkers for the Early
Diagnosis of Stroke: The Stroke-Chip Study.)
Bustamante A, López-C
Diagnosis of Stroke: Th Diagnosis of Stroke: The Stroke-Chip Study. *Stroke* 2017; 48: 2419–2425.
33. Montaner J, Mendioroz M, Delgado P, et al. Differentiating ischemic from
- Diagnosis of Stroke: The Stroke-Chip Study. *Stroke 2017*, 40. 2419–2425.
Montaner J, Mendioroz M, Delgado P, et al. Differentiating ischemic from
hemorrhagic stroke using plasma biomarkers: the S100B/RAGE pathway.
Proteo 133. Montrial Controller J, Mendinis Congrado P, Manuel Collectioning Protection Constrainers (September 2012;
133. Malicek D, Wittig I, Luger S, et al. Proteomics-Based Approach to Identify
- hemorrhagic stroke using plasma biomarkers: the S100B/RAGE pathway. J
Proteomics 2012; 75: 4758–4765.
Malicek D, Wittig I, Luger S, et al. Proteomics-Based Approach to Identify No
Blood Biomarker Candidates for Differentia Proteomics 2012; 75: 4750–4765.
Malicek D, Wittig I, Luger S, et al. P
Blood Biomarker Candidates for D
Ischemic Stroke-A Pilot Study. *Fro* 34. Malice D, Wittig J, 2018. The Protession Differentiating Intracerebral Hemorrhage From
Ischemic Stroke-A Pilot Study. *Front Neurol* 2021; 12: 713124.
35. Zhang J, Su X, Qi A, et al. Metabolomic profiling of fatty acid
- Ischemic Stroke-A Pilot Study. *Front Neurol* 2021; 12: 713124.
Zhang J, Su X, Qi A, et al. Metabolomic profiling of fatty acid biomarkers for
intracerebral hemorrhage stroke. *Talanta* 2021; 222: 121679. Ischemic Stroke-A Pilot Study. *Front Neurol* 2021; 12: 713124.
Zhang J, Su X, Qi A, et al. Metabolomic profiling of fatty acid bior
intracerebral hemorrhage stroke. *Talanta* 2021; 222: 121679.
- 36. Lopez MF, Sarracino DA, Prakash A, et al. Discrimination of ischemic and
hemorrhagic strokes using a multiplexed, mass spectrometry-based assay is intracerebral hemorrhage stroke. *Tulumu 2021, 222*: 121679.
Lopez MF, Sarracino DA, Prakash A, et al. Discrimination of iscl
hemorrhagic strokes using a multiplexed, mass spectrometry-l
apolipoproteins coupled to multi-ma 36. Lopez Lopez Martin 1999 Channels, Compositent Determination of the morrhagic strokes using a multiplexed, mass spectrometry-based assage apolipoproteins coupled to multi-marker ROC algorithm. Proteomics Cline
6: 190–20 apolipoproteins coupled to multi-marker ROC algorithm. Proteomics Clin Appl 2012;
6: 190–200.
- 37. Perry LA, Lucarelli T, Penny-Dimri JC, et al. Glial fibrillary acidic protein for the early
diagnosis of intracerebral hemorrhage: Systematic review and meta-analysis of diagnostic test accuracy. Int J Stroke 2019; 14: 390-399.
- 38. Zhang J, Zhang C-H, Lin X-L, et al. Serum glial fibrillary acidic protein as a biomarker diagnostic test accuracy. *Int J Stroke* 2019; 14: 390–399.
Zhang J, Zhang C-H, Lin X-L, et al. Serum glial fibrillary acidic protein as a biomar
for differentiating intracerebral hemorrhage and ischemic stroke in patients diagnostic test accuracy. *Int J Stroke 2019*, 14: 390–399.
Zhang J, Zhang C-H, Lin X-L, et al. Serum glial fibrillary ac
for differentiating intracerebral hemorrhage and ischem
symptoms of acute stroke: a systematic revie for differentiating intracerebral hemorrhage and ischemic stroke in patients with
symptoms of acute stroke: a systematic review and meta-analysis. Neurol Sci 2013;
34: 1887–1892. for an extracement areas and the term in patients of patients with symptoms of acute stroke: a systematic review and meta-analysis. *Neurol Sci* 2013
34: 1887–1892.
Sun Y, Qin Q, Shang Y-J, et al. The accuracy of glial fib
- symptoms of acute stroke: a systematic review and meta-analysis. *Neurol Scr* 2013;
34: 1887–1892.
Sun Y, Qin Q, Shang Y-J, et al. The accuracy of glial fibrillary acidic protein in acute
stroke differential diagnosis: A m Sun Y, Qin Q, Sha
stroke differenti
606. 39. Sun Y, Quin Q, Sunn J, Commercial Correlation, Separate International Stroke differential diagnosis: A meta-analysis. *Scand J Clin Lab Invest* 2013; 73: 60?
606.
40. Cabezas JA, Bustamante A, Giannini N, et al. Discri
- 606.
40. Cabezas JA, Bustamante A, Giannini N, et al. Discriminative value of glial fibrillar
acidic protein (GFAP) as a diagnostic tool in acute stroke. Individual patient data meta-analysis *J Investig Med* 2020; 68: 1379-1385. acidic protein (GFAP) as a diagnostic tool in acute stroke. Individual patient data
meta-analysis. *J Investig Med* 2020; 68: 1379–1385.
41. Kumar A, Misra S, Yadav AK, et al. Role of glial fibrillary acidic protein as a
- meta-analysis. *J Investig Med* 2020; 68: 1379–1385.
Kumar A, Misra S, Yadav AK, et al. Role of glial fibrillary acidic protein as a
biomarker in differentiating intracerebral haemorrhage from ischaemic stroke ar meta-analysis. J Investig Med 2020, 60: 1379–1305.
Kumar A, Misra S, Yadav AK, et al. Role of glial fibrill
biomarker in differentiating intracerebral haemorrh
stroke mimics: a meta-analysis. *Biomarkers* 2020; 2. biomarker in differentiating intracerebral haemorrhage from ischaemic st:
stroke mimics: a meta-analysis. *Biomarkers* 2020; 25: 1–8.
. stroke mimics: a meta-analysis. Biomarkers 2020; 25: $1-8$. stroke mimics: a meta-analysis. Biomarkers 2020; 25: 1–8.

- and D-dimer may differentiate acute stroke from stroke-mimicking conditions in the emergency department. *J Intern Med* 2011; 270: 166–174.
43. Kavalci C, Genchallac H, Durukan P, et al. Value of biomarker-based diagnosti
- and D-dimer may differentiate acute in the 2011; 270: 166–174.
Emergency department. *J Intern Med* 2011; 270: 166–174.
Kavalci C, Genchallac H, Durukan P, et al. Value of biomarker-based diagnostic test in
differential di emergency department. J Intern Med 2011, 270: 166–174.
Kavalci C, Genchallac H, Durukan P, et al. Value of biomark.
differential diagnosis of hemorrhagic-ischemic stroke. *Bra*
398–401. differential diagnosis of hemorrhagic-ischemic stroke. *Bratisl Lek Listy* 2011; 112:
398–401.
- differential diagnosis of hemorrhagic-ischemic stroke. *Bratisl Lek Listy 2*011, 112:
398–401.
Kim MH, Kang SY, Kim MC, et al. Plasma biomarkers in the diagnosis of acute
ischemic stroke. *Ann Clin Lab Sci* 2010; 40: 336–3 Kim MH, k
ischemic s
- 14. Ann Min Map Sci 2010; 40: 336–341.
45. Allard L, Lescuyer P, Burgess J, et al. ApoC-I and ApoC-III as potential plasmat
45. Allard L, Lescuyer P, Burgess J, et al. ApoC-I and ApoC-III as potential plasmat
45. Allard L, ischemic stroke. Ann chn Lab Scr 2010, 40: 336–341.
Allard L, Lescuyer P, Burgess J, et al. ApoC-I and ApoC
markers to distinguish between ischemic and hemori
4: 2242–2251. markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 2004;
4: 2242–2251.
- markers to distinguish between ischemic and hemorrhagic stroke. *Proteomics* 2004;
4: 2242–2251.
Walsh KB, Hart K, Roll S, et al. Apolipoprotein A-I and Paraoxonase-1 Are Potential
Blood Biomarkers for Ischemic Stroke Diag 46. Walsh KB, Hart K, Roll S, et al. Apolipoprotein A-I and Paraoxonase-1 Are Potential
Blood Biomarkers for Ischemic Stroke Diagnosis. *J Stroke Cerebrovasc Dis* 2016; 25
1360–1365. 46. Wallett, Finited String, Finited Stroke, Protector of and Parameters 2016; 25:
Blood Biomarkers for Ischemic Stroke Diagnosis. *J Stroke Cerebrovasc Dis* 2016; 25:
1360–1365. Blood Biomarkers for Ischemic Stroke Diagnosis. J Stroke Cerebrovasc Dis 2016, 25:
1360–1365.

Figure legends

Figure 1: Study flow diagram

Figure 2a: Volcano plot depicting the log₂ fold change on the x-axis and -log₁₀ p-value on the y-axis for the upregulated and downregulated proteins in 20 IS cases compared to 20 ICH cases within 24 hours. **Figure 2** to 20 ICH cases within 24 hours. Figure 2b: Feature selection using the Boruta random to 20 ICH cases within 24 hours. Figure 2b: Feature selection using the Boruta random
forest between 20 IS and 20 ICH cases within 24 hours. Figure 2c: Heatmap showing
the distribution and expression pattern of 20 signific forest between 20 IS and 20 ICH cases within 24 hours. Figure 2c: Heatmap showing
the distribution and expression pattern of 20 significantly differentially expressed
proteins between IS and ICH. Figure 2d: Protein-protein proteins between IS and ICH. Figure 2d: Protein-protein interaction network analysis of differentially expressed proteins between IS and ICH using the Cytoscape software.
The colour of nodes and edges represents the degree of interaction and interaction
score. The colour of nodes and edges represents the degree of interaction and interaction score.

Figure 3: A comparison between the ROC curves of Clinical prediction model (blue curve), Biomarker prediction model (red curve), and Combined prediction model (green curve) to differentiate IS from ICH within 24 hours. curve) to differentiate IS from ICH within 24 hours. curve) to differentiate IS from ICH within 24 hours.

Table 1: List of significantly differentially expressed proteins between IS and ICH within 24 hours of symptom onset using Fold change with p-value and Boruta random forest feature selection criteria

*Fold change is a ratio representing the change of protein concentration between IS and ICH patients.

Bold values: Fold change >1.5 or <0.67, p-value<0.05 and confirmed/tentative in Boruta random forest.

Abbreviations: A2M- Alpha-2-macroglobulin, MMP2- Matrix metalloproteinase 2 (72 kDa type IV collagenase), SERPING1- Plasma protease C1 inhibitor, HP-Haptoglobin, APOH- Apolipoprotein H (Beta-2-glycoprotein 1), RBP4- Retinol Binding protein 4, TF- Serotransferrin, PIGR- Polymeric immunoglobulin receptor, APOC1- Apolipoprotein C-I, APCS- Serum amyloid P-component, APOA1- Apolipoprotein A1, ORM2- Orosomucoid (Alpha-1-acid glycoprotein 2), FBXW5- F-

box/WD repeat-containing protein 5, MINPP1- Multiple inositol polyphosphate phosphatase 1, APOL1- Apolipoprotein L1, SERPINA11- Serpin A11, IGFBP3- Insulin-like growth factor-binding protein 3.

Table 2: The diagnostic potential of protein biomarkers assessed in the validation phase of the study to differentiate ischemic stroke from intracerebral hemorrhage within 24 hours of onset

S.	Protein Biomarker	OR (95% CI)	$p-$	Cutoff	Sensitivity	Specificity	PPV (95% CI)	NPV (95% CI)
No	(UniProt ID)		value		(95% CI)	(95% CI)	(For IS)	(For ICH)
	GFAP (P14136)	$0.06(0.03 \cdot 0.12)$	0.001	< 16.54	93% (88-97%)	55% (46-63%)	67% (60-74%)	89% (81-95%)
$\overline{2}$	MMP-9 (P14780)	0.15(0.07.0.32)	0.001	< 16.52	94% (89-97%)	30% (23-38%)	57% (51-63%)	83% (71-92%)
3	UCH-L1 (P09936)	$0.24(0.12\cdot 0.44)$	0.001	< 1403	90% (84-94%)	32% (25-40%)	57% (50-63%)	76% (64-86%)
$\overline{4}$	MINPP1 (Q9UNW1)	$0.39(0.24-0.62)$	0.001	19.93	73% (65-80%)	49% (41-58%)	59% (51-66%)	64% (55-73%)
5	APO-A1 (P02647)	$0.13(0.07-0.26)$	0.001	< 2192	92% (86-96%)	39% (31-48%)	60% (54-67%)	83% (72-91%)
6	Alpha-1-acid-	0.33(0.17.0.63)	0.001	< 20.29	24% (17-32%)	91% (85-95%)	72% (57-84%)	54% (48-61%)
	Glycoprotein (ORM2)							
	(P19652)							
$\overline{7}$	BNP (N=179) (P16860)	$0.38(0.20-0.72)$	0.003	< 946	74% (64-83%)	47% (36-58%)	59% (49-68%)	65% (52-76)
8	Beta-2-glycoprotein 1	$0.25(0.10\cdot0.65)$	0.004	< 20.25	96% (91-98%)	14% (9-21%)	53% (47-59%)	78% (58-91%)
	(APOH) (P02749)							
9	RBP4 (P02753)	$0.49(0.30\cdot0.80)$	0.005	17.32	75% (68-82%)	40% (32-48%)	56% (48-63%)	62% (51-71%)
10	MMP-2 (P08253)	0.54(0.33.0.89)	0.01	< 18.63	40% (32-48%)	73% (65-80%)	60% (48-70%)	55% (48-62%)
11	APO-C1 (P02654)	194 (115 - 329)	0.01	>16.26	80% (73-86%)	33% (25-41%)	54% (47-61%)	62% (50-73%)
12	Alpha-2-Macroglobulin	$0.56(0.34-0.93)$	0.02	< 18.70	75% (68-82%)	37% (29-45%)	54% (47-61%)	60% (49-70%)
	(P01023)							
13	IGFBP3 (P17936)	$0.53(0.30-0.95)$	0.03	17.10	85% (78-90%)	25% (18-33%)	53% (46-59%)	62% (49-74%)
14	Haptoglobin (P00738)	181 (101 3 22)	0.04	>17.21	85% (78-90%)	25% (18 32%)	53% (46-59%)	62% (48-74%)
15	Serotransferrin (P02787)	$0.51(0.26-0.99)$	0.04	< 2102	90% (84-94%)	18% (12-25%)	52% (46-58%)	64% (48-78%)

The cut-off values represent the Log₂ normalized protein concentrations.

Abbreviations: OR: Odds Ratio; CI: Confidence Interval; PPV: Positive Predictive Value; NPV: Negative Predictive Value; APO- Apolipoprotein; APOH: Apolipoprotein H (Beta-2-glycoprotein 1); MINPP1: Multiple inositol polyphosphate phosphatase 1; ORM2: Orosomucoid 2 (Alpha-1-acid glycoprotein 2); RBP4: Retinol Binding Protein 4; MMP- Matrix Metalloproteinase; MMP2: Matrix Metalloproteinase 2 (72 kDa type IV collagenase); A2M: Alpha-2-Macroglobulin; IGFBP3: Insulin-like growth factor-binding protein 3; FBXW5: F-box/WD repeat-containing protein 5; APCS: Serum amyloid P-component; SERPING1: Serpin Family G Member 1 (Plasma protease C1 inhibitor); GFAP: Glial Fibrillary Acidic Protein; UCH-L1: Ubiquitin C-Terminal Hydrolase L1; BNP: Brain Natriuretic Peptide.

Table 3: Multivariable prediction models to differentiate IS from ICH within 24 hours

Abbreviations: OR: Odds Ratio; CI: Confidence Interval; AUC: Area Under the Curve; NIHSS: National Institutes of Health Stroke Scale; GFAP: Glial Fibrillary Acidic Protein; MMP9: Matrix Metalloproteinase 9; Institutes of Health Stroke State; GFAP: Glial Fibrillary Actual Fibrillary Actual Proteins Metalloproteinase 9;
MDO: Anglia cantrix MPD-0, Graece stroke 1, Metalloproteinase 9; Metalloproteinase 9; MCU-14; Hispanitia, C APO: Apolipoprotein; ORM2: Orosomucoid 2 (Alpha-1-acid glycoprotein 2); UCH-L1: Ub iquitin C-Terminal Hydrolase L1.
Clinical model: Adjusted for age, sex, time taken to reach the hospital, hypertension, diabetes, atrial

fibrillation, current smoking, mild alcohol consumption, family history of diabetes, family history of heart attack, NIHSS score at admission and TLC. Biomarker model: Adjusted for GFAP, UCH-L1, MMP2, MMP9, RBP4, MINPP1, APO-A1, APO-C1, APOH, ORM2, Haptoglobin, Serotransferrin, A2M, and IGFBP3. RBP4, MINTP1, APO-A1, APO-C1, APOH, ORM2, Haptoglobin, Serotransferrin, A2M, and IGFB
Combined models Adjusted for sero buneautonsien strijel fibrilletien, surmant ameliae, MIICC seems at **Combined model:** Adjusted for sex, hypertension, atrial fibrination, current smoking, NIHSS score at a admission, GFAP, MMP9, and APO-C1.

Table 4: Comparison in the diagnostic performance of the three prediction models at different pre-test probabilities

Abbreviations: PPV: Positive Predicted Value; NPV: Negative Predictive Value; CI: Confidence Intervals; LR: Likelihood Ratio.